Immunocore (IMCR) to Release Earnings on Wednesday

Immunocore (NASDAQ:IMCR) is expected to release its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Immunocore to post earnings of ($0.28) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 2:00 AM ET.

Immunocore Stock Up 0.3%

Immunocore stock opened at $32.38 on Wednesday. The stock has a market capitalization of $1.64 billion, a PE ratio of -56.81 and a beta of 0.78. The business has a 50 day simple moving average of $34.02 and a 200-day simple moving average of $34.32. The company has a debt-to-equity ratio of 0.99, a current ratio of 6.00 and a quick ratio of 5.97. Immunocore has a 12 month low of $23.15 and a 12 month high of $40.71.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on IMCR. Wall Street Zen cut shares of Immunocore from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Zacks Research upgraded shares of Immunocore from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 7th. Morgan Stanley lifted their target price on Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a report on Monday, November 10th. Wells Fargo & Company initiated coverage on shares of Immunocore in a research report on Friday, October 31st. They issued an “overweight” rating and a $60.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $60.40.

Institutional Investors Weigh In On Immunocore

A number of institutional investors have recently added to or reduced their stakes in IMCR. Millennium Management LLC boosted its position in shares of Immunocore by 334.3% during the 3rd quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock worth $45,993,000 after purchasing an additional 974,463 shares in the last quarter. Bellevue Group AG grew its position in shares of Immunocore by 14.5% in the third quarter. Bellevue Group AG now owns 2,796,803 shares of the company’s stock valued at $101,608,000 after purchasing an additional 354,973 shares during the last quarter. Primecap Management Co. CA raised its position in shares of Immunocore by 5.5% during the 4th quarter. Primecap Management Co. CA now owns 3,961,880 shares of the company’s stock worth $137,517,000 after purchasing an additional 207,320 shares during the last quarter. Armistice Capital LLC lifted its position in shares of Immunocore by 21.5% in the third quarter. Armistice Capital LLC now owns 824,000 shares of the company’s stock valued at $29,936,000 after acquiring an additional 146,000 shares in the last quarter. Finally, Marshall Wace LLP boosted its stake in shares of Immunocore by 425.8% during the 2nd quarter. Marshall Wace LLP now owns 146,610 shares of the company’s stock worth $4,601,000 after purchasing an additional 118,728 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.